Trabectedin
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 958 publications
Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: March 03, 2026
Efficacy and safety of trabectedin and pegylated liposomal doxorubicin in elderly patients: a subgroup analysis of a retrospective cohort.
Journal: Journal of chemotherapy (Florence, Italy)
Published: January 23, 2026
Schlafen 11 as a prognostic and potentially predictive biomarker in soft tissue sarcoma: evidence from a real-world cohort.
Journal: Frontiers in oncology
Published: January 20, 2026
Acute myocardial infarction caused by coronary tumor embolism from uterine leiomyosarcoma: a case report.
Journal: Gynecologic oncology reports
Published: January 14, 2026
Characterisation of Bespoke Patient-Derived In Vitro Models of Ewing Sarcoma.
Journal: Cancers
Published: December 18, 2025
DCMiC: a double-cylinder micro-chamber platform for high-throughput drug screening and modeling of microenvironmental resistance in Ewing sarcoma.
Journal: Lab on a chip
Published: December 09, 2025
Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression.
Journal: Molecular therapy. Oncology
Published: October 15, 2025
Bidirectional Regulation in the Tumour Microenvironment: The Interaction Between Tumour-Associated Macrophages and T Cells Reshapes the Paradigm of Cancer Immunotherapy.
Journal: Immunology
Published: October 02, 2025
Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy.
Journal: Scientific reports
Published: September 27, 2025
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 24, 2025
Last Updated: 04/28/2026